Medical oncologists provide comprehensive insights on neoadjuvant therapy options for patients with melanoma.
Encorafenib Combo May Limit Recurrence Risk in BRAF V600+ Melanoma
Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.
OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma
John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.
RP1/Nivolumab Combo Shows Responses in Advanced Pretreated Melanoma
Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.
Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma
On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.
Nivolumab/Relatlimab Elicit IC Activity in Anti–PD-L1–Refractory Melanoma Brain Mets
The combination elicited a clinical benefit rate of 63.0% and an overall response rate of 22.2% in anti–PD-L1–refractory melanoma with melanoma brain metastases.
Relatlimab Shows Comparable Efficacy to Ipilimumab in Advanced Melanoma
Efficacy across most patient subgroups appeared to be consistent with relatlimab/nivolumab vs ipilimumab/nivolumab in patients with advanced melanoma.